Your guide to the coming quarter in biotech
Over the next three months, we’re going to find out whether the next wave of Covid-19 drugs have a shot, how the FDA feels about the first gene therapy for hemophilia, and whether, at last, Biogen is going to keep its promise in Alzheimer’s disease.
STAT rounded up all the major biotech events in the cards for the third quarter. That includes a bevy of expected data on treatments and vaccines for the novel coronavirus and a pair of weighty regulatory events that, were there no pandemic, would be the talk of the industry.
First, BioMarin is awaiting an FDA decision on what would be the first one-time treatment for hemophilia A. The company has mapped out a strategy for world domination in the competitive space, but the first step is convincing regulators that the benefits of its gene therapy outweigh the risks. Then, Biogen has pledged to submit its long-delayed Alzheimer’s treatment for approval in the third quarter. Whether it can meet that timeline has sweeping reputational importance for the company.
Read more.
STAT rounded up all the major biotech events in the cards for the third quarter. That includes a bevy of expected data on treatments and vaccines for the novel coronavirus and a pair of weighty regulatory events that, were there no pandemic, would be the talk of the industry.
First, BioMarin is awaiting an FDA decision on what would be the first one-time treatment for hemophilia A. The company has mapped out a strategy for world domination in the competitive space, but the first step is convincing regulators that the benefits of its gene therapy outweigh the risks. Then, Biogen has pledged to submit its long-delayed Alzheimer’s treatment for approval in the third quarter. Whether it can meet that timeline has sweeping reputational importance for the company.
Read more.
.png)
No hay comentarios:
Publicar un comentario